Source: Registered Drug Product Database (NG) Revision Year: 2025 Publisher: Manufacturer: Huazhong Pharmaceutical Co., Ltd. Site of Manufacture: No.118, Xianshan Road, Xiangyang City, Hubei Province, China
Cerebral oedema caused by brain tumours, neurosurgery, bacterial meningitis, brain abscess.
Severe acute asthma attack.
Oral initial treatment of extensive, severe, acute skin diseases that respond to glucocorticoids, such as erythroderma, pemphigus vulgaris, acute eczema.
Oral initial treatment of autoimmune diseases, such as systemic lupus erythematosus (especially visceral forms).
Severely progressive form of active rheumatoid arthritis, e.g. rapidly destructive forms and/or with extra-articular manifestations.
Severe infections with toxic conditions (e.g. tuberculosis, typhoid) only with concomitant anti-infective therapy.
Palliative treatment of malignant tumours.
Congenital adrenogenital syndrome in adulthood.
Dosage depends on the nature and severity of the disease and the individual response of the patient to treatment. In general, relatively high initial doses are administered, and they should be significantly higher in acute severe forms than in chronic diseases.
Unless otherwise prescribed, the following dosage recommendations apply:
The tablets should not be split to adjust doses. If patients need a dose that cannot be provided by one or more tablets of 0.5mg, other appropriate formulations should be used.
The tablets should be taken during or after a meal. They should be swallowed whole, with a sufficient amount of liquid. The daily dose should be administered as a single dose in the morning, if possible (circadian therapy). In patients who require a high-dose therapy because of their disease, multiple daily dosing is often required to achieve maximum effect.
Depending on the underlying disease, clinical symptoms and response to therapy, the dose can be reduced at a faster or slower rate and the therapy stopped, or the patient is stabilised on a maintenance dose as low as possible and, if necessary, adrenal axis monitored. Basically, the dose and duration of treatment should be kept as high and long as necessary, but as low and short as possible. In principle, the dose should be reduced gradually.
In long-term therapy which is deemed necessary following initial treatment, patients should be switched to prednisone/prednisolone, because this leads to lower adrenal suppression.
In hypothyroidism or liver cirrhosis, low doses may be sufficient or a dose reduction may be necessary.
Acute intoxications with dexamethasone are not known. In case of chronic overdosing, an increase in undesirable effects, especially endocrine, metabolic and electrolyte-related effects, can be expected (see section 4.8).
There is no known antidote to dexamethasone.
3 years.
Store in the original package in order to protect from light and moisture.
This medicinal product does not require any special temperature storage conditions.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.